About GTPase Era, mitochondrial
GTPase Era, mitochondrial (ERAL1) is a protein
from Homo sapiens identified by UniProt accession
O75616, 437 residues long.
MolForge cross-references it against 0 known binders and
96 disease associations.
Target properties
| Protein name | GTPase Era, mitochondrial |
| UniProt accession | O75616 |
| Gene | ERAL1 |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (96)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- Perrault syndrome · score 0.42
- Perrault syndrome 2 · score 0.37
- Perrault syndrome 1 · score 0.37
- Red cell distribution width · score 0.23
- reticulocyte count · score 0.22
- mean corpuscular hemoglobin concentration · score 0.21
- Immature Reticulocyte Fraction Measurement · score 0.20
- reticulocyte measurement · score 0.19
- mean corpuscular hemoglobin · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75616-F1 | alphafold | PREDICTED | 77.91 | — |
Amino-acid sequence (437 residues)
MAAPSWRGAR LVQSVLRVWQ VGPHVARERV IPFSSLLGFQ RRCVSCVAGS AFSGPRLASA SRSNGQGSAL DHFLGFSQPD SSVTPCVPAV SMNRDEQDVL LVHHPDMPEN SRVLRVVLLG APNAGKSTLS NQLLGRKVFP VSRKVHTTRC QALGVITEKE TQVILLDTPG IISPGKQKRH HLELSLLEDP WKSMESADLV VVLVDVSDKW TRNQLSPQLL RCLTKYSQIP SVLVMNKVDC LKQKSVLLEL TAALTEGVVN GKKLKMRQAF HSHPGTHCPS PAVKDPNTQS VGNPQRIGWP HFKEIFMLSA LSQEDVKTLK QYLLTQAQPG PWEYHSAVLT SQTPEEICAN IIREKLLEHL PQEVPYNVQQ KTAVWEEGPG GELVIQQKLL VPKESYVKLL IGPKGHVISQ IAQEAGHDLM DIFLCDVDIR LSVKLLK
Explore GTPase Era, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets